---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Long-term morbidity"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Long-term morbidity. Topics: Burden of repeated recurrence and surveillance with the bladder in place; Lifestyle effects of radical cystectomy and patient reluctance; Complications within 90 days of radical cystectomy; Adverse events and readmission after radical cystectomy compared with bladder-sparing therapy, CISTO cohort; 3 further topics. 7 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Burden of repeated recurrence and surveillance with the bladder in place

> “Even though most patients do not die of bladder cancer, the vast majority endures the morbidity of recurrence and progression of their cancer.”

Source: [Chamie et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3773281/)

> “Timely follow-up care after treatment is extremely important for people who still have their bladder because of the high likelihood of cancer recurrence or a subsequent bladder cancer.”

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.7-2"></a>

### Lifestyle effects of radical cystectomy and patient reluctance

> “but radical surgery comes with substantial risk”
> “and dramatic lifestyle changes. Further, many patients are unwilling to accept major surgery until all other possibilities are exhausted.”

Source: [Steinberg et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4927860/)

<a id="topic-2.2.1.7-3"></a>

### Complications within 90 days of radical cystectomy

> “Sixty-four percent (735/1142) of patients experienced a complication within 90 d of surgery.”
> “Overall, the highest grade of complication was grade 0 in 36% (n=407), grade 1-2 in 51% (n=582), and grade 3-5 in 13% (n=153).”
> “Gastrointestinal complications were most common (29%), followed by infectious complications (25%) and wound-related complications (15%).”

Source: [Shabsigh et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/18675501/)

<a id="topic-2.2.1.7-4"></a>

### Adverse events and readmission after radical cystectomy compared with bladder-sparing therapy, CISTO cohort

> “Participants who selected RC were significantly more likely to experience AEs (62% v 38% for BST; wRR, 1.61 [95% CI, 1.35 to 1.91],”
> “including gastrointestinal, infectious, wound, thromboembolic, and bleeding complications.”
> “Among participants who selected RC, 15 (8.0%) experienced prolonged hospitalization after their RC, 57 (30%) were readmitted within 90 days, and five (2.5%) died within 90 days”
> “while BST was associated with better bowel and sexual health.”

Source: [Gore et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12707586/)

<a id="topic-2.2.1.7-5"></a>

### Long-term complications of conduit urinary diversion

> “There were 643 (60.8%) patients with 1,453 complications directly attributable to the urinary diversion performed with a mean of 2.3 complications per patient.”
> “Bowel complications were the most common, occurring in 215 patients (20.3%), followed by renal complications in 213 (20.2%), infectious complications in 174 (16.5%), stomal complications in 163 (15.4%) and urolithiasis in 162 (15.3%).”
> “Long-term followup of these patients is necessary to closely monitor for potential complications from the urinary diversion that can occur decades later.”

Source: [Shimko et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21168867/)

<a id="topic-2.2.1.7-6"></a>

### Kidney function decline after cystectomy with urinary diversion

> “Among 563 patients who underwent cystectomy with urinary diversion, a NB was used for 72 (12.8%) individuals.”
> “Both NB and IC patients had decreased kidney function over time, with mean GFR losses at 5 years of 17% and 14% of baseline values, respectively.”

Source: [Faraj et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32482512/)

<a id="topic-2.2.1.7-7"></a>

### Late complications after robot-assisted radical cystectomy with intracorporeal urinary diversion

> “The mean follow-up was 30 ± 22 months.”
> “The stenosis rate of uretero-ileal anastomosis was 14%, while a reduction in eGFR (≥ 20%) was observed in about half of the cases.”
> “UTIs occurred in 37% of the patients, especially in the first 12 months.”

Source: [Presicce et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8217047/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
